CLAIMS:

1. Use of Lurbinectedin in the manufacture of a medicament for the treatment of cancer, wherein lurbinectedin is to be administered in combination with doxorubicin; and wherein doxorubicin is to be administered at a dose of 30mg/m^2 or less during each administration cycle, or at a dose of less than 30mg/m^2 during each administration cycle.

2. The use according to claim 1, wherein lurbinectedin is to be administered in combination with doxorubicin; and wherein doxorubicin is to be administered at a dose between 15 to 30 mg/m^2, or between 20 to 30 mg/m^2, or between 15 to less than 30 mg/m^2, or between 20 to less than 30 mg/m^2 during each administration cycle.

3. The use according to any of the previous claims, wherein lurbinectedin is to be administered in combination with doxorubicin; and wherein doxorubicin is to be administered at a dose between 15 to 25 mg/m^2, or between 20 to 25 mg/m^2, preferably about 25 mg/m^2, preferably 25 mg/m^2, during each administration cycle.

4. The use according to any of the previous claims, wherein doxorubicin is to be administered at a dose of about 25 mg/m^2.

5. The use according to any of the previous claims, wherein a single dose doxorubicin is to be administered at each administration cycle.

6. The use according to any of the previous claims, wherein lurbinectedin is to be administered at a dose of between 2 mg/m^2 to 4 mg/m^2, higher than 2 mg/m^2 and lower than 4 mg/m^2, between 2,5 and 3,5 mg/m^2, preferably about 3.2 mg/m^2, preferably 3.2 mg/m^2 body surface area during each administration cycle.

7. The use according to any of the previous claims, wherein lurbinectedin is to be administered at a dose of about 3.2 mg/m^2.

8. The use according to any of the previous claims, wherein the administration cycle is every three to four weeks, preferably every 21 days.

9. The use according to any of the previous claims, wherein lurbinectedin is to be administered on day 1 (D1) of each cycle; or wherein doxorubicin is to be administered on day 1 (D1) of each cycle; or wherein lurbinectedin and doxorubicin are to be administered on day 1 (D1) of each cycle.

o

10. The use according to any of the previous claims, wherein in combination with doxorubicin 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 administration cycles are administered; preferably 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 administration cycles, preferably 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 administration cycles.

11. The use according to any of the previous claims, wherein doxorubicin is to be administered first, followed by lurbinectedin administration.

12. The use according to any of the previous claims, wherein lurbinectedin is to be administered as 1 hour intravenous infusion during each administration cycle; or wherein doxorubicin is to be administered as 1 hour intravenous infusion during each administration cycle; wherein lurbinectedin and doxorubicin are to be administered as 1 hour intravenous infusion during each administration cycle.

13. The use according to any of the previous claims, wherein lurbinectedin is to be administered in combination with doxorubicin, wherein lurbinectedin is to be administered at a dose of about 3.2mg/m^2 on D1 of each administration cycle; and wherein doxorubicin is to be administered at a dose of about 25mg/m^2 administered on D1 of each administration cycle; and wherein each administration cycle is 21 days.

14. The use according to any of the previous claims, wherein the method further comprises administration of granulocyte-colony stimulating factor (G-CSF).

15. The use according to claim 14, wherein G-CSF is to be administered on day 1 of an administration cycle; or wherein the patient receives primary prophylaxis with G-CSF starting 24-72 hours after day 1 of an administration cycle, and for five days.

16. The use according to claim 14 or claim 15, wherein G-CSF is to be administered during the first administration cycle; optionally wherein G-CSF during one or more subsequent administration cycles.

17. The use according to any of the previous claims, wherein after combination administration of lurbinectedin and doxorubicin during a first phase; lurbinectedin is to be administered alone for one or more cycles during a second phase; wherein lurbinectedin may be administered according to one or more of claims 6 to 9, 12 or 14 to 16.

o

18. The use according to claim 1, wherein the cancer is sarcoma, preferably a soft tissue sarcoma.

19. The use according to claim 18, wherein the soft tissue sarcoma is selected from from leiomyosarcoma, gastrointestinal stromal tumour, liposarcoma, dedifferentiated liposarcoma, undifferentiated pleomorphic sarcoma, malignant peripheral nerve sheath tumors, angiosarcoma, hemangioendothelioma, solitary fibrous tumor, fibrosarcoma, dermatofibrosarcoma protuberans, low-grade fibromyxoid sarcoma, endometrial stromal sarcoma, myxofibrosarcoma, fibromatosis, follicular dendritic cell sarcoma, desmoplastic small round cell tumour, pleomorphic liposarcoma, and synovial sarcoma.

20. The use according to claim 19, wherein the soft tissue sarcoma is advanced or metastatic leiomyosarcoma, selected from somatic soft tissue leiomyosarcoma, cutaneous or subcutaneous leiomyosarcoma, leiomyosarcoma of vascular origin, and leiomyosarcoma of uterine or non- uterine origin.

21. Use of lurbinectedin in the manufacture of a medicament for the treatment of cancer, said treatment comprises:

i) administering to the patient one or more cycles of lurbinectedin in combination with doxorubicin in a first phase according to any one of claims 1 to 20, and

ii) administering to the patient one or more cycles of lurbinectedin alone in a second phase; wherein lurbinectedin may be administered according to one or more of claims 6 to 9, 12 or 14 to 16.

22. A pharmaceutical package comprising lurbinectedin, together with instructions for its use in combination with doxorubicin according to any one of claims 1 to 21.

o